110
Participants
Start Date
October 1, 2018
Primary Completion Date
June 30, 2021
Study Completion Date
October 30, 2021
Evolocumab 140 MG/ML
Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is a protein that targets LDL receptors for degradation and thereby reduces the liver's ability to remove LDL-C.
Centro de Pesquisa Clinica - FCM/Unicamp, Campinas
University of Campinas, Brazil
OTHER